Details for Patent: 9,567,363

Which drugs does patent 9,567,363 protect, and when does it expire?

Patent 9,567,363 protects INQOVI and is included in one NDA.

This patent has forty-four patent family members in thirty-five countries.

Summary for Patent: 9,567,363

Title:	Certain compounds, compositions and methods
Abstract:	The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.
Inventor(s):	Gregory S. Hamilton, Takashi Tsukamoto, Dana V. Ferraris, Bridget Duvall, Rena Lapidus
Assignee:	Taiho Pharmaceutical Co Ltd
Application Number:	US14/584,437
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,567,363

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes				Y

International Family Members for US Patent 9,567,363

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2207786		301256	Netherlands
European Patent Office	2207786		301257	Netherlands
European Patent Office	2207786		CA 2023 00037	Denmark
European Patent Office	2207786		CA 2023 00038	Denmark
European Patent Office	2207786		LUC00326	Luxembourg